{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:22:30Z","timestamp":1787062950317,"version":"build-2736575974"},"reference-count":125,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:00:00Z","timestamp":1759968000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"the National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82371917"],"award-info":[{"award-number":["82371917"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biometals"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10534-025-00747-w","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:34:15Z","timestamp":1760006055000},"page":"1707-1730","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Progress and prospects of metal-based immunotherapy in breast cancer"],"prefix":"10.1007","volume":"38","author":[{"given":"Jiaxin","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinming","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,9]]},"reference":[{"issue":"1","key":"747_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52952-1","volume":"14","author":"MA Abdel-Mohsen","year":"2024","unstructured":"Abdel-Mohsen MA, Badawy AM, Abu-Youssef MA, Yehia MA, Abou Shamaa LD, Mohamed SA (2024) Influence of copper(I) nicotinate complex on the Notch1 signaling pathway in triple negative breast cancer cell lines. Sci Rep 14(1):2522. https:\/\/doi.org\/10.1038\/s41598-024-52952-1","journal-title":"Sci Rep"},{"issue":"1","key":"747_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-022-00500-3","volume":"8","author":"FO Ademuyiwa","year":"2022","unstructured":"Ademuyiwa FO, Gao F, Street CR, Chen I, Northfelt DW, Wesolowski R, Arora M, Brufsky A, Dees EC, Santa-Maria CA, Connolly RM, Force J, Moreno-Aspitia A, Herndon JM, Carmody M, Davies SR, Larson S, Pfaff KL, Jones SM, Weirather JL, Giobbie-Hurder A, Rodig SJ, Liu Z, Hagemann IS, Sharon E, Gillanders WE (2022) A randomized phase 2 study of neoadjuvant carboplatin and paclitaxel with or without atezolizumab in triple negative breast cancer (TNBC) - NCI 10013. NPJ Breast Cancer 8(1):134. https:\/\/doi.org\/10.1038\/s41523-022-00500-3","journal-title":"NPJ Breast Cancer"},{"issue":"15","key":"747_CR3","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.2174\/1568026043387421","volume":"4","author":"E Alessio","year":"2004","unstructured":"Alessio E, Mestroni G, Bergamo A, Sava G (2004) Ruthenium antimetastatic agents. Curr Top Med Chem 4(15):1525\u20131535. https:\/\/doi.org\/10.2174\/1568026043387421","journal-title":"Curr Top Med Chem"},{"key":"747_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.radonc.2024.110372","volume":"197","author":"S Alkner","year":"2024","unstructured":"Alkner S, Wieslander E, Lundstedt D, Berg M, Kristensen I, Andersson Y, Bergkvist L, Frisell J, Olofsson Bagge R, Sund M, Christiansen P, Davide Gentilini O, Kontos M, Kuhn T, Reimer T, Ryden L, Filtenborg Tvedskov T, Vrou Offersen B, Dahl Nissen H, de Boniface J, Group, S. T. (2024) Quality assessment of radiotherapy in the prospective randomized SENOMAC trial. Radiother Oncol 197:110372. https:\/\/doi.org\/10.1016\/j.radonc.2024.110372","journal-title":"Radiother Oncol"},{"issue":"6","key":"747_CR5","doi-asserted-by":"publisher","first-page":"2115","DOI":"10.1002\/med.21971","volume":"43","author":"M Ashrafizadeh","year":"2023","unstructured":"Ashrafizadeh M, Zarrabi A, Bigham A, Taheriazam A, Saghari Y, Mirzaei S, Hashemi M, Hushmandi K, Karimi-Maleh H, Nazarzadeh Zare E, Sharifi E, Ertas YN, Rabiee N, Sethi G, Shen M (2023) (Nano)platforms in breast cancer therapy: drug\/gene delivery, advanced nanocarriers and immunotherapy. Med Res Rev 43(6):2115\u20132176. https:\/\/doi.org\/10.1002\/med.21971","journal-title":"Med Res Rev"},{"key":"747_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15122750","author":"Y Bai","year":"2023","unstructured":"Bai Y, Aodeng G, Ga L, Hai W, Ai J (2023) Research progress of metal anticancer drugs. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics15122750","journal-title":"Pharmaceutics"},{"issue":"3","key":"747_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s13205-022-03121-6","volume":"12","author":"P Banthia","year":"2022","unstructured":"Banthia P, Gambhir L, Sharma A, Daga D, Kapoor N, Chaudhary R, Sharma G (2022) Nano to rescue: repository of nanocarriers for targeted drug delivery to curb breast cancer. 3 Biotech 12(3):70. https:\/\/doi.org\/10.1007\/s13205-022-03121-6","journal-title":"3 Biotech"},{"issue":"23","key":"747_CR8","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1200\/JCO.2016.71.4147","volume":"35","author":"JL Blum","year":"2017","unstructured":"Blum JL, Flynn PJ, Yothers G, Asmar L, Geyer CE Jr, Jacobs SA, Robert NJ, Hopkins JO, O\u2019Shaughnessy JA, Dang CT, Gomez HL, Fehrenbacher L, Vukelja SJ, Lyss AP, Paul D, Brufsky AM, Jeong JH, Colangelo LH, Swain SM, Wolmark N (2017) Anthracyclines in early breast cancer: the abc trials-USOR 06\u2013090, NSABP B-46-I\/USOR 07132, and NSABP B-49 (NRG Oncology). J Clin Oncol 35(23):2647\u20132655. https:\/\/doi.org\/10.1200\/JCO.2016.71.4147","journal-title":"J Clin Oncol"},{"key":"747_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.radonc.2019.08.021","volume":"142","author":"KJ Borm","year":"2020","unstructured":"Borm KJ, Oechsner M, Dusberg M, Buschner G, Weber W, Combs SE, Duma MN (2020) Irradiation of regional lymph node areas in breast cancer - Dose evaluation according to the Z0011, AMAROS, EORTC 10981\u201322023 and MA-20 field design. Radiother Oncol 142:195\u2013201. https:\/\/doi.org\/10.1016\/j.radonc.2019.08.021","journal-title":"Radiother Oncol"},{"issue":"3","key":"747_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Jemal A (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74(3):229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"747_CR11","doi-asserted-by":"publisher","first-page":"405","DOI":"10.3760\/cma.j.cn112152-20210113-00045","volume":"43","author":"Breast Cancer Expert Committee of National Cancer Quality Control, C., & Cancer Drug Clinical Research Committee of China Anti-Cancer, A","year":"2021","unstructured":"Breast Cancer Expert Committee of National Cancer Quality Control, C., & Cancer Drug Clinical Research Committee of China Anti-Cancer, A (2021) Consensus recommendations for the clinical application of CDK4\/6 inhibitors in patients with hormone receptor positive, human epidermal growth factor receptor 2 negative advanced breast cancer. Zhonghua Zhong Liu Za Zhi 43(4):405\u2013413. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20210113-00045","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"747_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s13578-023-01151-y","author":"MA Bustos","year":"2023","unstructured":"Bustos MA, Yokoe T, Shoji Y, Kobayashi Y, Mizuno S, Murakami T, Zhang X, Sekhar SC, Kim S, Ryu S, Knarr M, Vasilev SA, DiFeo A, Drapkin R, Hoon DSB (2023) Mir-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer. Cell Biosci. https:\/\/doi.org\/10.1186\/s13578-023-01151-y","journal-title":"Cell Biosci"},{"issue":"11","key":"747_CR13","doi-asserted-by":"publisher","first-page":"4199","DOI":"10.1021\/acs.molpharmaceut.2c00572","volume":"19","author":"Z Cai","year":"2022","unstructured":"Cai Z, Liu R, Chan C, Lu Y, Winnik MA, Cescon DW, Reilly RM (2022) (90)Y-labeled gold nanoparticle depot (NPD) combined with anti-PD-L1 antibodies strongly inhibits the growth of 4T1 tumors in immunocompetent mice and induces an abscopal effect on a distant non-irradiated tumor. Mol Pharm 19(11):4199\u20134211. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00572","journal-title":"Mol Pharm"},{"key":"747_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.bios.2020.112452","volume":"166","author":"Y Cao","year":"2020","unstructured":"Cao Y, Wang Y, Yu X, Jiang X, Li G, Zhao J (2020) Identification of programmed death ligand-1 positive exosomes in breast cancer based on DNA amplification-responsive metal-organic frameworks. Biosens Bioelectron 166:112452. https:\/\/doi.org\/10.1016\/j.bios.2020.112452","journal-title":"Biosens Bioelectron"},{"issue":"2","key":"747_CR15","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1002\/cncr.24756","volume":"116","author":"MG Carmichael","year":"2010","unstructured":"Carmichael MG, Benavides LC, Holmes JP, Gates JD, Mittendorf EA, Ponniah S, Peoples GE (2010) Results of the first phase 1 clinical trial of the HER-2\/neu peptide (GP2) vaccine in disease-free breast cancer patients: United States military cancer institute clinical trials group study I-04. Cancer 116(2):292\u2013301. https:\/\/doi.org\/10.1002\/cncr.24756","journal-title":"Cancer"},{"key":"747_CR16","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-018-0285-7","author":"L Chablani","year":"2019","unstructured":"Chablani L, Tawde SA, Akalkotkar A, D\u2019Souza MJ (2019) Evaluation of a particulate breast cancer vaccine delivered via skin. AAPS J. https:\/\/doi.org\/10.1208\/s12248-018-0285-7","journal-title":"AAPS J"},{"issue":"13","key":"747_CR17","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1158\/1078-0432.CCR-21-4313","volume":"28","author":"L Chen","year":"2022","unstructured":"Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, Yu KD, Fan L, Li JJ, Hou YF, Hu Z, Chen CM, Huang XY, Cao AY, Hu X, Zhao S, Ma XY, Xu Y, Sun XJ, Chai W-J, Guo X, Chen X, Zhu X-Y, Zou J-J, Yang W-T, Wang Z-H, Shao ZM (2022a) Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer (FUTURE-C-Plus): an open-label, single-arm, phase II trial. Clin Cancer Res 28(13):2807\u20132817. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-4313","journal-title":"Clin Cancer Res"},{"key":"747_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.865554","volume":"13","author":"XY Chen","year":"2022","unstructured":"Chen XY, Yung LL, Tan PH, Bay BH (2022b) Harnessing the Immunogenic Potential of Gold Nanoparticle-Based Platforms as a Therapeutic Strategy in Breast Cancer Immunotherapy: A Mini Review. Front Immunol 13:865554. https:\/\/doi.org\/10.3389\/fimmu.2022.865554","journal-title":"Front Immunol"},{"key":"747_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121371","volume":"281","author":"Q Chen","year":"2022","unstructured":"Chen Q, He L, Li X, Xu L, Chen T (2022c) Ruthenium complexes boost NK cell immunotherapy via sensitizing triple-negative breast cancer and shaping immuno-microenvironment. Biomaterials 281:121371. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121371","journal-title":"Biomaterials"},{"issue":"43","key":"747_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202403201","volume":"20","author":"Q Chen","year":"2024","unstructured":"Chen Q, Peng B, Lin L, Chen J, Jiang Z, Luo Y, Huang L, Li J, Peng Y, Wu J, Li W, Zhuang K, Liang M (2024) Chondroitin sulfate-modified hydroxyapatite for caspase-1 activated induced pyroptosis through Ca overload\/ER stress\/STING\/IRF3 pathway in colorectal cancer. Small 20(43):e2403201. https:\/\/doi.org\/10.1002\/smll.202403201","journal-title":"Small"},{"key":"747_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12649","author":"L Chen","year":"2025","unstructured":"Chen L, Wu WY, Liang F, Liu GY, Yu KD, Wu J, Di GH, Fan L, Wang ZH, Li JJ, Shao ZM (2025) A prospective, phase II, neoadjuvant study based on chemotherapy sensitivity in HR+\/HER2- breast cancer-FINEST study. Cancer Commun. https:\/\/doi.org\/10.1002\/cac2.12649","journal-title":"Cancer Commun"},{"issue":"42","key":"747_CR22","doi-asserted-by":"publisher","first-page":"29121","DOI":"10.1021\/acsnano.4c10603","volume":"18","author":"X Cheng","year":"2024","unstructured":"Cheng X, He C, Huang J, Li J, Hu Z, Wang L, Wei T, Cui L, Lu M, Mi P, Xu J (2024) A tumor-homing nanoframework for synergistic microwave tumor ablation and provoking strong anticancer immunity against metastasis. ACS Nano 18(42):29121\u201329139. https:\/\/doi.org\/10.1021\/acsnano.4c10603","journal-title":"ACS Nano"},{"issue":"10265","key":"747_CR23","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1016\/S0140-6736(20)32531-9","volume":"396","author":"J Cortes","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS, Nowecki Z, Im SA, Yusof MM, Gallardo C, Lipatov O, Barrios CH, Holgado E, Iwata H, Masuda N, Otero MT, Gokmen E, Loi S, Guo Z, Zhao J, Aktan G, Karantza V, Investigators K (2020) Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 396(10265):1817\u20131828. https:\/\/doi.org\/10.1016\/S0140-6736(20)32531-9","journal-title":"Lancet"},{"issue":"43","key":"747_CR24","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202402101","volume":"20","author":"M Cui","year":"2024","unstructured":"Cui M, Qian L, Lu K, Liu J, Chu B, Wu X, Dong F, Song B, He Y (2024) Defect-rich metastable MoS(2) promotes macrophage reprogramming in breast cancer: a clinical perspective. Small 20(43):e2402101. https:\/\/doi.org\/10.1002\/smll.202402101","journal-title":"Small"},{"issue":"13","key":"747_CR25","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1056\/NEJMoa2313487","volume":"390","author":"J de Boniface","year":"2024","unstructured":"de Boniface J, Filtenborg Tvedskov T, Ryden L, Szulkin R, Reimer T, Kuhn T, Kontos M, Gentilini OD, Olofsson Bagge R, Sund M, Lundstedt D, Appelgren M, Ahlgren J, Norenstedt S, Celebioglu F, Sackey H, Scheel Andersen I, Hoyer U, Nyman PF, Vikhe Patil E, Wieslander E, Dahl Nissen H, Alkner S, Andersson Y, Offersen BV, Bergkvist L, Frisell J, Christiansen P, Group, S. T. (2024) Omitting axillary dissection in breast cancer with sentinel-node metastases. N Engl J Med 390(13):1163\u20131175. https:\/\/doi.org\/10.1056\/NEJMoa2313487","journal-title":"N Engl J Med"},{"key":"747_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.154958","volume":"127","author":"A Dey","year":"2020","unstructured":"Dey A, Manna S, Kumar S, Chattopadhyay S, Saha B, Roy S (2020) Immunostimulatory effect of chitosan conjugated green copper oxide nanoparticles in tumor immunotherapy. Cytokine 127:154958. https:\/\/doi.org\/10.1016\/j.cyto.2019.154958","journal-title":"Cytokine"},{"issue":"1","key":"747_CR27","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF01877380","volume":"6","author":"P Dufour","year":"1993","unstructured":"Dufour P, Lang JM, Giron C, Duclos B, Haehnel P, Jaeck D, Jung JM, Oberling F (1993) Sodium dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy 6(1):9\u201312. https:\/\/doi.org\/10.1007\/BF01877380","journal-title":"Biotherapy"},{"issue":"2","key":"747_CR28","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.1021\/acs.chemrev.8b00396","volume":"119","author":"B Englinger","year":"2019","unstructured":"Englinger B, Pirker C, Heffeter P, Terenzi A, Kowol CR, Keppler BK, Berger W (2019) Metal drugs and the anticancer immune response. Chem Rev 119(2):1519\u20131624. https:\/\/doi.org\/10.1021\/acs.chemrev.8b00396","journal-title":"Chem Rev"},{"issue":"6","key":"747_CR29","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.mattod.2017.11.022","volume":"21","author":"ER Evans","year":"2018","unstructured":"Evans ER, Bugga P, Asthana V, Drezek R (2018) Metallic nanoparticles for cancer immunotherapy. Mater Today 21(6):673\u2013685. https:\/\/doi.org\/10.1016\/j.mattod.2017.11.022","journal-title":"Mater Today"},{"key":"747_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102496","volume":"112","author":"C Falato","year":"2023","unstructured":"Falato C, Schettini F, Pascual T, Braso-Maristany F, Prat A (2023) Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. Cancer Treat Rev 112:102496. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102496","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"747_CR31","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/S1470-2045(23)00579-X","volume":"25","author":"L Fan","year":"2024","unstructured":"Fan L, Wang ZH, Ma LX, Wu SY, Wu J, Yu KD, Sui XY, Xu Y, Liu XY, Chen L, Zhang WJ, Jin X, Xiao Q, Shui RH, Xiao Y, Wang H, Yang YS, Huang XY, Cao AY, Li J-J, Di G-H, Liu G-Y, Yang W-T, Hu X, Xia Y, Liang Q-N, Jiang Y-Z, Shao ZM (2024) Optimising first-line subtyping-based therapy in triple-negative breast cancer (FUTURE-SUPER): a multi-cohort, randomised, phase 2 trial. Lancet Oncol 25(2):184\u2013197. https:\/\/doi.org\/10.1016\/S1470-2045(23)00579-X","journal-title":"Lancet Oncol"},{"issue":"24","key":"747_CR32","doi-asserted-by":"publisher","first-page":"24883","DOI":"10.1021\/acsnano.3c05898","volume":"17","author":"Y Fang","year":"2023","unstructured":"Fang Y, Huang S, Hu Q, Zhang J, King JA, Wang Y, Wei Z, Lu J, He Z, Kong X, Yang X, Ji J, Li J, Zhai G, Ye L (2023) Injectable zwitterionic physical hydrogel with enhanced chemodynamic therapy and tumor microenvironment remodeling properties for synergistic anticancer therapy. ACS Nano 17(24):24883\u201324900. https:\/\/doi.org\/10.1021\/acsnano.3c05898","journal-title":"ACS Nano"},{"issue":"6","key":"747_CR33","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1158\/2326-6066.CIR-16-0284","volume":"5","author":"JB Foote","year":"2017","unstructured":"Foote JB, Kok M, Leatherman JM, Armstrong TD, Marcinkowski BC, Ojalvo LS, Kanne DB, Jaffee EM, Dubensky TW Jr., Emens LA (2017) A sting agonist given with OX40 receptor and PD-L1 modulators primes immunity and reduces tumor growth in tolerized mice. Cancer Immunol Res 5(6):468\u2013479. https:\/\/doi.org\/10.1158\/2326-6066.CIR-16-0284","journal-title":"Cancer Immunol Res"},{"key":"747_CR34","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.actbio.2024.06.025","volume":"184","author":"W Gao","year":"2024","unstructured":"Gao W, Wang Y, Wang P, Kan W, Wang M, Li H, Wang X, Yuan P, Ma Y, Zhang J, Tian G, Zhang G (2024) Biosynthetic MnSe nanobomb with low Mn content activates the cGAS-STING pathway and induces immunogenic cell death to enhance antitumour immunity. Acta Biomater 184:383\u2013396. https:\/\/doi.org\/10.1016\/j.actbio.2024.06.025","journal-title":"Acta Biomater"},{"issue":"4","key":"747_CR35","doi-asserted-by":"publisher","first-page":"3711","DOI":"10.1002\/jcp.29265","volume":"235","author":"N Gholami","year":"2020","unstructured":"Gholami N, Cohan RA, Razavi A, Bigdeli R, Dashbolaghi A, Asgary V (2020) Cytotoxic and apoptotic properties of a novel nano-toxin formulation based on biologically synthesized silver nanoparticle loaded with recombinant truncated pseudomonas exotoxin A. J Cell Physiol 235(4):3711\u20133720. https:\/\/doi.org\/10.1002\/jcp.29265","journal-title":"J Cell Physiol"},{"issue":"8","key":"747_CR36","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","volume":"22","author":"A Goldhirsch","year":"2011","unstructured":"Goldhirsch A, Wood WC, Coates AS, Gelber RD, Th\u00fcrlimann B, Senn HJ (2011) Strategies for subtypes\u2014dealing with the diversity of breast cancer: highlights of the St. Gallen international expert consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22(8):1736\u20131747. https:\/\/doi.org\/10.1093\/annonc\/mdr304","journal-title":"Ann Oncol"},{"issue":"22","key":"747_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202307961","volume":"20","author":"X Guan","year":"2024","unstructured":"Guan X, Zeng N, Zhao Y, Huang X, Lai S, Shen G, Zhang W, Wang N, Yao W, Guo Y, Yang R, Wang Z, Jiang X (2024) Dual-modality imaging-guided manganese-based nanotransformer for enhanced gas-photothermal therapy combined immunotherapeutic strategy against triple-negative breast cancer. Small 20(22):e2307961. https:\/\/doi.org\/10.1002\/smll.202307961","journal-title":"Small"},{"issue":"6","key":"747_CR38","doi-asserted-by":"publisher","first-page":"5670","DOI":"10.1021\/nn5002112","volume":"8","author":"L Guo","year":"2014","unstructured":"Guo L, Yan DD, Yang D, Li Y, Wang X, Zalewski O, Yan B, Lu W (2014) Combinatorial photothermal and immuno cancer therapy using chitosan-coated hollow copper sulfide nanoparticles. ACS Nano 8(6):5670\u20135681. https:\/\/doi.org\/10.1021\/nn5002112","journal-title":"ACS Nano"},{"issue":"7","key":"747_CR39","doi-asserted-by":"publisher","DOI":"10.1002\/smtd.202300230","volume":"7","author":"H He","year":"2023","unstructured":"He H, Du L, Xue H, An Y, Zeng K, Huang H, He Y, Zhang C, Wu J, Shuai X (2023) Triple tumor microenvironment-responsive ferroptosis pathways induced by manganese-based imageable nanoenzymes for enhanced breast cancer theranostics. Small Methods 7(7):e2300230. https:\/\/doi.org\/10.1002\/smtd.202300230","journal-title":"Small Methods"},{"key":"747_CR40","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1080\/00325481.1964.11695054","volume":"35","author":"RC Hickey","year":"1964","unstructured":"Hickey RC (1964) Radical mastectomy and extended radical mastectomy. Postgrad Med 35:307\u2013310. https:\/\/doi.org\/10.1080\/00325481.1964.11695054","journal-title":"Postgrad Med"},{"key":"747_CR41","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.00938","author":"RX Hong","year":"2025","unstructured":"Hong RX, Xu F, Xia W, Teng YE, Ouyang QC, Zheng QF, Yuan ZY, Chen DS, Jiang KK, Lin Y, Dai Z, Liu XL, Chen QJ, Wu XH, Shi YX, Huang JJ, An X, Xue C, Bi XW, Chen M-T, Li H, Yao H-R, Zou G-R, Huang H, Zhang J-M, Wang SS (2025) Metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer-the phase III MECCA trial. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.24.00938","journal-title":"J Clin Oncol"},{"issue":"1","key":"747_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-021-00342-5","volume":"7","author":"SA Hurvitz","year":"2021","unstructured":"Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, Fasching PA, Ejlertsen B, Yang EH, Glaspy JA, Slamon DJ (2021) A careful reassessment of anthracycline use in curable breast cancer. NPJ Breast Cancer 7(1):134. https:\/\/doi.org\/10.1038\/s41523-021-00342-5","journal-title":"NPJ Breast Cancer"},{"issue":"14","key":"747_CR43","doi-asserted-by":"publisher","first-page":"17129","DOI":"10.1021\/acsami.3c18569","volume":"16","author":"Y Jang","year":"2024","unstructured":"Jang Y, Cho YS, Kim A, Zhou X, Kim Y, Wan Z, Moon JJ, Park H (2024) CXCR4-targeted macrophage-derived biomimetic hybrid vesicle nanoplatform for enhanced cancer therapy through codelivery of manganese and doxorubicin. ACS Appl Mater Interfaces 16(14):17129\u201317144. https:\/\/doi.org\/10.1021\/acsami.3c18569","journal-title":"ACS Appl Mater Interfaces"},{"issue":"1","key":"747_CR44","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/s41591-023-02677-x","volume":"30","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, Ouyang Q, Sun T, Zhang Q, Teng Y, Cui J, Wang H, Yin Y, Wang X, Zhou X, Wang Y, Sun G, Wang J, Zhang L, Yang J, Qian J, Yan M, Liu X, Yi T, Cheng Y, Li M, Zang A, Wang S, Wang C, Wu X, Cheng J, Li H, Lin Y, Geng C, Gu K, Xie C, Xiong H, Li Q, Chen Y, Li F, Zhang A, Zhang Y, Wu Y, Nie J, Liu Q, Wang K, Mo X, Chen L, Pan Y, Fu P, Zhang H, Pang D, Sheng Y, Han Y, Cang S, Luo X, Yu W, Deng R, Yang C, Keegan P (2024a) Toripalimab plus nab-paclitaxel in metastatic or recurrent triple-negative breast cancer: a randomized phase 3 trial. Nat Med 30(1):249\u2013256. https:\/\/doi.org\/10.1038\/s41591-023-02677-x","journal-title":"Nat Med"},{"issue":"1","key":"747_CR45","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1186\/s12951-024-02525-1","volume":"22","author":"Z Jiang","year":"2024","unstructured":"Jiang Z, Cai G, Liu H, Liu L, Huang R, Nie X, Gui R, Li J, Ma J, Cao K, Luo Y (2024b) A combination of a TLR7\/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune. J Nanobiotechnology 22(1):296. https:\/\/doi.org\/10.1186\/s12951-024-02525-1","journal-title":"J Nanobiotechnology"},{"issue":"51","key":"747_CR46","doi-asserted-by":"publisher","first-page":"23313","DOI":"10.1002\/anie.202011273","volume":"59","author":"S Jin","year":"2020","unstructured":"Jin S, Muhammad N, Sun Y, Tan Y, Yuan H, Song D, Guo Z, Wang X (2020) Multispecific platinum(IV) complex deters breast cancer via interposing inflammation and immunosuppression as an inhibitor of COX-2 and PD-L1. Angew Chem Int Ed Engl 59(51):23313\u201323321. https:\/\/doi.org\/10.1002\/anie.202011273","journal-title":"Angew Chem Int Ed Engl"},{"issue":"10","key":"747_CR47","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1038\/s41588-023-01507-7","volume":"55","author":"X Jin","year":"2023","unstructured":"Jin X, Zhou YF, Ma D, Zhao S, Lin CJ, Xiao Y, Fu T, Liu CL, Chen YY, Xiao WX, Liu YQ, Chen QW, Yu Y, Shi LM, Shi JX, Huang W, Robertson JFR, Jiang YZ, Shao ZM (2023) Molecular classification of hormone receptor-positive HER2-negative breast cancer. Nat Genet 55(10):1696\u20131708. https:\/\/doi.org\/10.1038\/s41588-023-01507-7","journal-title":"Nat Genet"},{"key":"747_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2022.110173","volume":"367","author":"K Jomova","year":"2022","unstructured":"Jomova K, Makova M, Alomar SY, Alwasel SH, Nepovimova E, Kuca K, Rhodes CJ, Valko M (2022) Essential metals in health and disease. Chem Biol Interact 367:110173. https:\/\/doi.org\/10.1016\/j.cbi.2022.110173","journal-title":"Chem Biol Interact"},{"key":"747_CR49","doi-asserted-by":"publisher","first-page":"181","DOI":"10.2147\/IJN.S219042","volume":"15","author":"M Khoobchandani","year":"2020","unstructured":"Khoobchandani M, Katti KK, Karikachery AR, Thipe VC, Srisrimal D, Dhurvas Mohandoss DK, Darshakumar RD, Joshi CM, Katti KV (2020) New approaches in breast cancer therapy through green nanotechnology and nano-ayurvedic medicine - pre-clinical and pilot human clinical investigations. Int J Nanomedicine 15:181\u2013197. https:\/\/doi.org\/10.2147\/IJN.S219042","journal-title":"Int J Nanomedicine"},{"issue":"8","key":"747_CR50","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1038\/s41571-019-0232-2","volume":"16","author":"D Killock","year":"2019","unstructured":"Killock D (2019) Chemotherapy as a tonic to invigorate PD-1 inhibition in TNBC. Nat Rev Clin Oncol 16(8):464. https:\/\/doi.org\/10.1038\/s41571-019-0232-2","journal-title":"Nat Rev Clin Oncol"},{"issue":"11","key":"747_CR51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011987.pub2","volume":"11","author":"I Kindts","year":"2017","unstructured":"Kindts I, Laenen A, Depuydt T, Weltens C (2017) Tumour bed boost radiotherapy for women after breast-conserving surgery. Cochrane Database Syst Rev 11(11):CD011987. https:\/\/doi.org\/10.1002\/14651858.CD011987.pub2","journal-title":"Cochrane Database Syst Rev"},{"issue":"13","key":"747_CR52","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1200\/JCO.20.03399","volume":"39","author":"LA Korde","year":"2021","unstructured":"Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, Khan SA, Loibl S, Morris EA, Perez A, Regan MM, Spears PA, Sudheendra PK, Symmans WF, Yung RL, Harvey BE, Hershman DL (2021) Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO guideline. J Clin Oncol 39(13):1485\u20131505. https:\/\/doi.org\/10.1200\/JCO.20.03399","journal-title":"J Clin Oncol"},{"issue":"1","key":"747_CR53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1158\/2159-8290.CD-19-0761","volume":"10","author":"J Kwon","year":"2020","unstructured":"Kwon J, Bakhoum SF (2020) The cytosolic DNA-sensing cGAS-STING pathway in cancer. Cancer Discov 10(1):26\u201339. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0761","journal-title":"Cancer Discov"},{"issue":"7","key":"747_CR54","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1158\/2326-6066.CIR-21-0826","volume":"10","author":"KM Lee","year":"2022","unstructured":"Lee KM, Lin CC, Servetto A, Bae J, Kandagatla V, Ye D, Kim G, Sudhan DR, Mendiratta S, Gonzalez Ericsson PI, Balko JM, Lee J, Barnes S, Malladi VS, Tabrizi S, Reddy SM, Yum S, Chang CW, Hutchinson KE, Arteaga CL (2022) Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple-negative breast cancer. Cancer Immunol Res 10(7):829\u2013843. https:\/\/doi.org\/10.1158\/2326-6066.CIR-21-0826","journal-title":"Cancer Immunol Res"},{"issue":"5","key":"747_CR55","doi-asserted-by":"publisher","first-page":"4814","DOI":"10.1002\/jcp.29358","volume":"235","author":"J Lei","year":"2020","unstructured":"Lei J, Wang H, Zhu D, Wan Y, Yin L (2020) Combined effects of avasimibe immunotherapy, doxorubicin chemotherapy, and metal-organic frameworks nanoparticles on breast cancer. J Cell Physiol 235(5):4814\u20134823. https:\/\/doi.org\/10.1002\/jcp.29358","journal-title":"J Cell Physiol"},{"key":"747_CR56","doi-asserted-by":"publisher","first-page":"1192434","DOI":"10.3389\/fphar.2023.1192434","volume":"14","author":"J Li","year":"2023","unstructured":"Li J, Zhang W, Ma X, Wei Y, Zhou F, Li J, Zhang C, Yang Z (2023a) Cuproptosis\/ferroptosis-related gene signature is correlated with immune infiltration and predict the prognosis for patients with breast cancer. Front Pharmacol 14:1192434. https:\/\/doi.org\/10.3389\/fphar.2023.1192434","journal-title":"Front Pharmacol"},{"key":"747_CR57","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.jconrel.2023.08.046","volume":"362","author":"G Li","year":"2023","unstructured":"Li G, Zhang J, Zhang S, Teng L, Sun F (2023b) Multifunctional nanoadjuvant-driven microenvironment modulation for enhanced photothermal immunotherapy in breast cancer. J Control Release 362:309\u2013324. https:\/\/doi.org\/10.1016\/j.jconrel.2023.08.046","journal-title":"J Control Release"},{"issue":"35","key":"747_CR58","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202403520","volume":"11","author":"Y Li","year":"2024","unstructured":"Li Y, Liu J, Weichselbaum RR, Lin W (2024a) Mitochondria-targeted multifunctional nanoparticles combine cuproptosis and programmed cell death-1 downregulation for cancer immunotherapy. Adv Sci 11(35):e2403520. https:\/\/doi.org\/10.1002\/advs.202403520","journal-title":"Adv Sci"},{"issue":"13","key":"747_CR59","doi-asserted-by":"publisher","first-page":"9584","DOI":"10.1021\/acsnano.3c13038","volume":"18","author":"C Li","year":"2024","unstructured":"Li C, Clauson R, Bugada LF, Ke F, He B, Yu Z, Chen H, Jacobovitz B, Hu H, Chuikov P, Hill BD, Rizvi SM, Song Y, Sun K, Axenov P, Huynh D, Wang X, Garmire L, Lei YL, Sun D (2024b) Antigen-clustered nanovaccine achieves long-term tumor remission by promoting B\/CD 4 T cell crosstalk. ACS Nano 18(13):9584\u20139604. https:\/\/doi.org\/10.1021\/acsnano.3c13038","journal-title":"ACS Nano"},{"issue":"36","key":"747_CR60","doi-asserted-by":"publisher","first-page":"8368","DOI":"10.1039\/d0tb01391a","volume":"8","author":"S Liang","year":"2020","unstructured":"Liang S, Sun M, Lu Y, Shi S, Yang Y, Lin Y, Feng C, Liu J, Dong C (2020) Cytokine-induced killer cells-assisted tumor-targeting delivery of Her-2 monoclonal antibody-conjugated gold nanostars with NIR photosensitizer for enhanced therapy of cancer. J Mater Chem B 8(36):8368\u20138382. https:\/\/doi.org\/10.1039\/d0tb01391a","journal-title":"J Mater Chem B"},{"issue":"4","key":"747_CR61","doi-asserted-by":"publisher","first-page":"2841","DOI":"10.1021\/acsnano.3c07123","volume":"18","author":"K Ling","year":"2024","unstructured":"Ling K, Zheng J, Jiang X, Huang W, Mai Y, Liao C, Fan S, Bu J, Li R, Zeng B, Zheng Q, Huang R, Li Z, Wong NK, Jiang H (2024) Mn(2+)\/CpG oligodeoxynucleotides codecorated black phosphorus nanosheet platform for enhanced antitumor potency in multimodal therapy. ACS Nano 18(4):2841\u20132860. https:\/\/doi.org\/10.1021\/acsnano.3c07123","journal-title":"ACS Nano"},{"issue":"8","key":"747_CR62","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/annonc\/mdz158","volume":"30","author":"S Loibl","year":"2019","unstructured":"Loibl S, Untch M, Burchardi N, Huober J, Sinn BV, Blohmer JU, Grischke EM, Furlanetto J, Tesch H, Hanusch C, Engels K, Rezai M, Jackisch C, Schmitt WD, von Minckwitz G, Thomalla J, Kummel S, Rautenberg B, Fasching PA, Weber K, Rhiem K, Denkert C, Schneeweiss A (2019) A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple-negative breast cancer: clinical results and biomarker analysis of GeparNuevo study. Ann Oncol 30(8):1279\u20131288. https:\/\/doi.org\/10.1093\/annonc\/mdz158","journal-title":"Ann Oncol"},{"key":"747_CR63","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2210845","author":"X Lu","year":"2023","unstructured":"Lu X, Wang X, Cheng H, Wang X, Liu C, Tan X (2023a) Anti-triple-negative breast cancer metastasis efficacy and molecular mechanism of the STING agonist for innate immune pathway. Ann Med. https:\/\/doi.org\/10.1080\/07853890.2023.2210845","journal-title":"Ann Med"},{"issue":"1","key":"747_CR64","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2210845","volume":"55","author":"X Lu","year":"2023","unstructured":"Lu X, Wang X, Cheng H, Wang X, Liu C, Tan X (2023b) Anti-triple-negative breast cancer metastasis efficacy and molecular mechanism of the STING agonist for innate immune pathway. Ann Med 55(1):2210845. https:\/\/doi.org\/10.1080\/07853890.2023.2210845","journal-title":"Ann Med"},{"key":"747_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.101317","author":"X Lu","year":"2024","unstructured":"Lu X, Deng W, Wang S, Zhao S, Zhu B, Bai B, Mao Y, Lin J, Yi Y, Xie Z, Wang X, Lu Y, Huang X, You T, Chen X, Sun W, Shen X (2024a) PEGylated Elesclomol@Cu(\u2161)-based metal-organic framework with effective nanozyme performance and cuproptosis induction efficacy for enhanced PD-L1-based immunotherapy. Mater Today Bio. https:\/\/doi.org\/10.1016\/j.mtbio.2024.101317","journal-title":"Mater Today Bio"},{"key":"747_CR66","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2024.101317","volume":"29","author":"X Lu","year":"2024","unstructured":"Lu X, Deng W, Wang S, Zhao S, Zhu B, Bai B, Mao Y, Lin J, Yi Y, Xie Z, Wang X, Lu Y, Huang X, You T, Chen X, Sun W, Shen X (2024b) PEGylated Elesclomol@Cu(\u2161)-based metal-organic framework with effective nanozyme performance and cuproptosis induction efficacy for enhanced PD-L1-based immunotherapy. Mater Today Bio 29:101317. https:\/\/doi.org\/10.1016\/j.mtbio.2024.101317","journal-title":"Mater Today Bio"},{"issue":"47","key":"747_CR67","doi-asserted-by":"publisher","first-page":"17601","DOI":"10.1039\/d3dt02543h","volume":"52","author":"Z Luo","year":"2023","unstructured":"Luo Z, Sheng Y, Jiang C, Pan Y, Wang X, Nezamzadeh-Ejhieh A, Ouyang J, Lu C, Liu J (2023) Recent advances and prospects of metal-organic frameworks in cancer therapies. Dalton Trans 52(47):17601\u201317622. https:\/\/doi.org\/10.1039\/d3dt02543h","journal-title":"Dalton Trans"},{"issue":"18","key":"747_CR68","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202301059","volume":"62","author":"J Ma","year":"2023","unstructured":"Ma J, Wang S, Zhao C, Yan X, Ren Q, Dong Z, Qiu J, Liu Y, Shan Q, Xu M, Yan B, Liu S (2023) Computer-aided discovery of potent broad-spectrum vaccine adjuvants. Angew Chem Int Ed Engl 62(18):e202301059. https:\/\/doi.org\/10.1002\/anie.202301059","journal-title":"Angew Chem Int Ed Engl"},{"key":"747_CR69","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1258013","volume":"14","author":"C Massa","year":"2023","unstructured":"Massa C, Seliger B (2023) Combination of multiple omics techniques for a personalized therapy or treatment selection. Front Immunol 14:1258013. https:\/\/doi.org\/10.3389\/fimmu.2023.1258013","journal-title":"Front Immunol"},{"issue":"38","key":"747_CR70","doi-asserted-by":"publisher","first-page":"10465","DOI":"10.1039\/d0sc03628e","volume":"11","author":"RT Mertens","year":"2020","unstructured":"Mertens RT, Parkin S, Awuah SG (2020) Cancer cell-selective modulation of mitochondrial respiration and metabolism by potent organogold(iii) dithiocarbamates. Chem Sci 11(38):10465\u201310482. https:\/\/doi.org\/10.1039\/d0sc03628e","journal-title":"Chem Sci"},{"issue":"7","key":"747_CR71","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1093\/annonc\/mdw150","volume":"27","author":"EA Mittendorf","year":"2016","unstructured":"Mittendorf EA, Ardavanis A, Symanowski J, Murray JL, Shumway NM, Litton JK, Hale DF, Perez SA, Anastasopoulou EA, Pistamaltzian NF, Ponniah S, Baxevanis CN, von Hofe E, Papamichail M, Peoples GE (2016) Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. Ann Oncol 27(7):1241\u20131248. https:\/\/doi.org\/10.1093\/annonc\/mdw150","journal-title":"Ann Oncol"},{"issue":"10257","key":"747_CR72","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","volume":"396","author":"EA Mittendorf","year":"2020","unstructured":"Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, Koehler A, Sohn J, Iwata H, Telli ML, Ferrario C, Punie K, Penault-Llorca F, Patel S, Duc AN, Liste-Hermoso M, Maiya V, Molinero L, Chui SY, Harbeck N (2020) Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial. Lancet 396(10257):1090\u20131100. https:\/\/doi.org\/10.1016\/S0140-6736(20)31953-X","journal-title":"Lancet"},{"issue":"9","key":"747_CR73","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1038\/s41591-024-03088-2","volume":"30","author":"H Mo","year":"2024","unstructured":"Mo H, Yu Y, Sun X, Ge H, Yu L, Guan X, Zhai J, Zhu A, Wei Y, Wang J, Yan X, Qian H, Xu B, Ma F (2024) Metronomic chemotherapy plus anti-PD-1 in metastatic breast cancer: a Bayesian adaptive randomized phase 2 trial. Nat Med 30(9):2528\u20132539. https:\/\/doi.org\/10.1038\/s41591-024-03088-2","journal-title":"Nat Med"},{"issue":"5","key":"747_CR74","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1016\/j.matt.2019.06.007","volume":"1","author":"K Ni","year":"2019","unstructured":"Ni K, Lan G, Chan C, Duan X, Guo N, Veroneau SS, Weichselbaum RR, Lin W (2019) Ultrathin metal-organic layer-mediated radiotherapy-radiodynamic therapy enhances immunotherapy of metastatic cancers. Matter 1(5):1331\u20131353","journal-title":"Matter"},{"issue":"14","key":"747_CR75","doi-asserted-by":"publisher","first-page":"9766","DOI":"10.1021\/acs.jmedchem.3c00586","volume":"66","author":"V Novohradsky","year":"2023","unstructured":"Novohradsky V, Marco A, Markova L, Cutillas N, Ruiz J, Brabec V (2023) Ir(III) compounds containing a terdentate ligand are potent inhibitors of proliferation and effective antimetastatic agents in aggressive triple-negative breast cancer cells. J Med Chem 66(14):9766\u20139783. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00586","journal-title":"J Med Chem"},{"issue":"1","key":"747_CR76","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1080\/21691401.2023.2270023","volume":"51","author":"SK P","year":"2023","unstructured":"P SK (2023) Cancer reduction in mice with Prakasine nanomedicine immunotherapy. Artif Cells Nanomed Biotechnol 51(1):572\u2013589. https:\/\/doi.org\/10.1080\/21691401.2023.2270023","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"747_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121449","volume":"283","author":"WL Pan","year":"2022","unstructured":"Pan WL, Tan Y, Meng W, Huang NH, Zhao YB, Yu ZQ, Huang Z, Zhang WH, Sun B, Chen JX (2022) Microenvironment-driven sequential ferroptosis, photodynamic therapy, and chemotherapy for targeted breast cancer therapy by a cancer-cell-membrane-coated nanoscale metal-organic framework. Biomaterials 283:121449. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121449","journal-title":"Biomaterials"},{"issue":"23","key":"747_CR78","doi-asserted-by":"publisher","first-page":"17593","DOI":"10.1021\/acs.inorgchem.1c02193","volume":"60","author":"RL Panchangam","year":"2021","unstructured":"Panchangam RL, Rao RN, Balamurali MM, Hingamire TB, Shanmugam D, Manickam V, Chanda K (2021) Antitumor effects of Ir(III)-2H-indazole complexes for triple negative breast cancer. Inorg Chem 60(23):17593\u201317607. https:\/\/doi.org\/10.1021\/acs.inorgchem.1c02193","journal-title":"Inorg Chem"},{"issue":"1","key":"747_CR79","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-019-6253-5","volume":"19","author":"JGP Pandy","year":"2019","unstructured":"Pandy JGP, Balolong-Garcia JC, Cruz-Ordinario MVB, Que FVF (2019) Triple negative breast cancer and platinum-based systemic treatment: a meta-analysis and systematic review. BMC Cancer 19(1):1065. https:\/\/doi.org\/10.1186\/s12885-019-6253-5","journal-title":"BMC Cancer"},{"issue":"6","key":"747_CR80","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1158\/2159-8290.CD-18-1218","volume":"9","author":"C Pantelidou","year":"2019","unstructured":"Pantelidou C, Sonzogni O, De Oliveria Taveira M, Mehta AK, Kothari A, Wang D, Visal T, Li MK, Pinto J, Castrillon JA, Cheney EM, Bouwman P, Jonkers J, Rottenberg S, Guerriero JL, Wulf GM, Shapiro GI (2019) PARP inhibitor efficacy depends on CD8(+) T-cell recruitment via intratumoral STING pathway activation in BRCA-deficient models of triple-negative breast cancer. Cancer Discov 9(6):722\u2013737. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1218","journal-title":"Cancer Discov"},{"issue":"1","key":"747_CR81","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1186\/s12951-024-03013-2","volume":"22","author":"J Peng","year":"2024","unstructured":"Peng J, Quan DL, Yang G, Wei LT, Yang Z, Dong ZY, Zou YM, Hou YK, Chen JX, Lv L, Sun B (2024) Multifunctional nanocomposites utilizing ruthenium (II) complex\/manganese (IV) dioxide nanoparticle for synergistic reinforcing radioimmunotherapy. J Nanobiotechnology 22(1):735. https:\/\/doi.org\/10.1186\/s12951-024-03013-2","journal-title":"J Nanobiotechnology"},{"issue":"8","key":"747_CR82","doi-asserted-by":"publisher","first-page":"1868","DOI":"10.1016\/j.biotechadv.2015.10.013","volume":"33","author":"P Peres Lde","year":"2015","unstructured":"Peres Lde P, da Luz FA, Pultz Bdos A, Brigido PC, de Araujo RA, Goulart LR, Silva MJ (2015) Peptide vaccines in breast cancer: The immunological basis for clinical response. Biotechnol Adv 33(8):1868\u20131877. https:\/\/doi.org\/10.1016\/j.biotechadv.2015.10.013","journal-title":"Biotechnol Adv"},{"issue":"10","key":"747_CR83","doi-asserted-by":"publisher","first-page":"3165","DOI":"10.1021\/acs.nanolett.3c05146","volume":"24","author":"M Qian","year":"2024","unstructured":"Qian M, Jiang G, Guo W, Huang R (2024) A biodegradable nanosuspension locally used for inhibiting postoperative recurrence and brain metastasis of breast cancer. Nano Lett 24(10):3165\u20133175. https:\/\/doi.org\/10.1021\/acs.nanolett.3c05146","journal-title":"Nano Lett"},{"issue":"10","key":"747_CR84","doi-asserted-by":"publisher","first-page":"2738","DOI":"10.1200\/JCO.1996.14.10.2738","volume":"14","author":"T Saphner","year":"1996","unstructured":"Saphner T, Tormey DC, Gray R (1996) Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 14(10):2738\u20132746. https:\/\/doi.org\/10.1200\/JCO.1996.14.10.2738","journal-title":"J Clin Oncol"},{"issue":"1","key":"747_CR85","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/S1470-2045(19)30689-8","volume":"21","author":"P Schmid","year":"2020","unstructured":"Schmid P, Rugo HS, Adams S, Schneeweiss A, Barrios CH, Iwata H, Dieras V, Henschel V, Molinero L, Chui SY, Maiya V, Husain A, Winer EP, Loi S, Emens LA, Investigators IM (2020a) Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 21(1):44\u201359. https:\/\/doi.org\/10.1016\/S1470-2045(19)30689-8","journal-title":"Lancet Oncol"},{"issue":"9","key":"747_CR86","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Foukakis T, Fasching PA, Cardoso F, Untch M, Jia L, Karantza V, Zhao J, Aktan G, Investigators K (2020b) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810\u2013821. https:\/\/doi.org\/10.1056\/NEJMoa1910549","journal-title":"N Engl J Med"},{"issue":"6","key":"747_CR87","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMoa2112651","volume":"386","author":"P Schmid","year":"2022","unstructured":"Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S, Bergh J, Denkert C, Park YH, Hui R, Harbeck N, Takahashi M, Untch M, Fasching PA, Cardoso F, Andersen J, Patt D, Danso M, Ferreira M, Mouret-Reynier M-A, Im S-A, Ahn J-H, Gion M, Baron-Hay S, Boileau J-F, Ding Yu, Tryfonidis K, Aktan G, Karantza V, O\u2019Shaughnessy J (2022) Event-free survival with Pembrolizumab in early Triple-negative breast cancer. N Engl J Med 386(6):556\u2013567. https:\/\/doi.org\/10.1056\/NEJMoa2112651","journal-title":"N Engl J Med"},{"key":"747_CR88","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"A Schneeweiss","year":"2018","unstructured":"Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Waldron-Lynch M, Eng-Wong J, Kirk S, Cortes J (2018) Long-term efficacy analysis of the randomised, phase II TRYPHAENA cardiac safety study: evaluating pertuzumab and trastuzumab plus standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer. Eur J Cancer 89:27\u201335. https:\/\/doi.org\/10.1016\/j.ejca.2017.10.021","journal-title":"Eur J Cancer"},{"issue":"32","key":"747_CR89","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202203523","volume":"9","author":"M Shen","year":"2022","unstructured":"Shen M, Chen C, Guo Q, Wang Q, Liao J, Wang L, Yu J, Xue M, Duan Y, Zhang J (2022) Systemic delivery of mPEG-masked trispecific T-cell nanoengagers in synergy with STING agonists overcomes immunotherapy resistance in TNBC and generates a vaccination effect. Adv Sci (Weinh) 9(32):e2203523. https:\/\/doi.org\/10.1002\/advs.202203523","journal-title":"Adv Sci (Weinh)"},{"issue":"7684","key":"747_CR90","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nature25016","volume":"552","author":"Z Skrott","year":"2017","unstructured":"Skrott Z, Mistrik M, Andersen KK, Friis S, Majera D, Gursky J, Ozdian T, Bartkova J, Turi Z, Moudry P, Kraus M, Michalova M, Vaclavkova J, Dzubak P, Vrobel I, Pouckova P, Sedlacek J, Miklovicova A, Kutt A, Li J, Mattova J, Driessen C, Dou QP, Olsen J, Hajduch M, Cvek B, Deshaies RJ, Bartek J (2017) Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature 552(7684):194\u2013199. https:\/\/doi.org\/10.1038\/nature25016","journal-title":"Nature"},{"issue":"11","key":"747_CR91","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s41565-021-00962-9","volume":"16","author":"X Sun","year":"2021","unstructured":"Sun X, Zhang Y, Li J, Park KS, Han K, Zhou X, Xu Y, Nam J, Xu J, Shi X, Wei L, Lei YL, Moon JJ (2021) Amplifying STING activation by cyclic dinucleotide-manganese particles for local and systemic cancer metalloimmunotherapy. Nat Nanotechnol 16(11):1260\u20131270. https:\/\/doi.org\/10.1038\/s41565-021-00962-9","journal-title":"Nat Nanotechnol"},{"issue":"12","key":"747_CR92","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202307278","volume":"11","author":"L Sun","year":"2024","unstructured":"Sun L, Gao H, Wang H, Zhou J, Ji X, Jiao Y, Qin X, Ni D, Zheng X (2024a) Nanoscale metal-organic frameworks-mediated degradation of mutant p53 proteins and activation of cGAS-STING pathway for enhanced cancer immunotherapy. Adv Sci (Weinh) 11(12):e2307278. https:\/\/doi.org\/10.1002\/advs.202307278","journal-title":"Adv Sci (Weinh)"},{"issue":"34","key":"747_CR93","doi-asserted-by":"publisher","first-page":"23727","DOI":"10.1021\/acsnano.4c08613","volume":"18","author":"W Sun","year":"2024","unstructured":"Sun W, Wang H, Qi Y, Li M, Zhang R, Gao Z, Cui J, Yu D (2024b) Metal-phenolic vehicles potentiate cycle-cascade activation of pyroptosis and cGAS-STING pathway for tumor immunotherapy. ACS Nano 18(34):23727\u201323740. https:\/\/doi.org\/10.1021\/acsnano.4c08613","journal-title":"ACS Nano"},{"key":"747_CR94","doi-asserted-by":"publisher","DOI":"10.1016\/j.nano.2023.102678","volume":"50","author":"J Tian","year":"2023","unstructured":"Tian J, Wang J, Xu H, Zou B, Chen W, Liu Y, Chen J, Zhang R (2023) Nanoscale metal-organic framework delivers rapamycin to induce tissue immunogenic cell death and potentiates cancer immunotherapy. Nanomedicine 50:102678. https:\/\/doi.org\/10.1016\/j.nano.2023.102678","journal-title":"Nanomedicine"},{"issue":"25","key":"747_CR95","doi-asserted-by":"publisher","first-page":"3351","DOI":"10.1200\/JCO.2010.31.4930","volume":"29","author":"M Untch","year":"2011","unstructured":"Untch M, Fasching PA, Konecny GE, Hasmuller S, Lebeau A, Kreienberg R, Camara O, Muller V, du Bois A, Kuhn T, Stickeler E, Harbeck N, Hoss C, Kahlert S, Beck T, Fett W, Mehta KM, von Minckwitz G, Loibl S (2011) Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups. J Clin Oncol 29(25):3351\u20133357. https:\/\/doi.org\/10.1200\/JCO.2010.31.4930","journal-title":"J Clin Oncol"},{"issue":"4","key":"747_CR96","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1038\/s43018-023-00542-x","volume":"4","author":"L Voorwerk","year":"2023","unstructured":"Voorwerk L, Isaeva OI, Horlings HM, Balduzzi S, Chelushkin M, Bakker NAM, Champanhet E, Garner H, Sikorska K, Loo CE, Kemper I, Mandjes IAM, de Maaker M, van Geel JJL, Boers J, de Boer M, Salgado R, van Dongen MGJ, Sonke GS, de Visser KE, Schumacher TN, Blank CU, Wessels LFA, Jager A, Tjan-Heijnen VCG, Schr\u00f6der CP, Linn SC, Kok M (2023) PD-L1 blockade in combination with carboplatin as immune induction in metastatic lobular breast cancer: the GELATO trial. Nat Cancer 4(4):535\u2013549. https:\/\/doi.org\/10.1038\/s43018-023-00542-x","journal-title":"Nat Cancer"},{"issue":"5","key":"747_CR97","doi-asserted-by":"publisher","first-page":"6442","DOI":"10.1021\/acsami.2c19476","volume":"15","author":"X Wang","year":"2023","unstructured":"Wang X, Luo J, Wang J, Cao J, Hong Y, Wen Q, Zeng Y, Shi Z, Ma G, Zhang T, Huang P (2023) Catalytically active metal-organic frameworks elicit robust immune response to combination chemodynamic and checkpoint blockade immunotherapy. ACS Appl Mater Interfaces 15(5):6442\u20136455. https:\/\/doi.org\/10.1021\/acsami.2c19476","journal-title":"ACS Appl Mater Interfaces"},{"key":"747_CR98","doi-asserted-by":"publisher","first-page":"794","DOI":"10.1016\/j.jconrel.2024.10.049","volume":"376","author":"X Wang","year":"2024","unstructured":"Wang X, Yang Y, Wang P, Li Q, Gao W, Sun Y, Tian G, Zhang G, Xiao J (2024) Oxygen self-supplying nanoradiosensitizer activates cGAS-STING pathway to enhance radioimmunotherapy of triple negative breast cancer. J Control Release 376:794\u2013805. https:\/\/doi.org\/10.1016\/j.jconrel.2024.10.049","journal-title":"J Control Release"},{"issue":"50","key":"747_CR99","doi-asserted-by":"publisher","first-page":"17031","DOI":"10.1002\/chem.201302671","volume":"19","author":"MI Webb","year":"2013","unstructured":"Webb MI, Wu B, Jang T, Chard RA, Wong EW, Wong MQ, Yapp DT, Walsby CJ (2013) Increasing the bioavailability of Ru(III) anticancer complexes through hydrophobic albumin interactions. Chemistry 19(50):17031\u201317042. https:\/\/doi.org\/10.1002\/chem.201302671","journal-title":"Chemistry"},{"issue":"45","key":"747_CR100","doi-asserted-by":"publisher","first-page":"14263","DOI":"10.1021\/acs.nanolett.4c03862","volume":"24","author":"X Wei","year":"2024","unstructured":"Wei X, Sun L, Deng J, Yang Q, Zhao J, Zhou S (2024) A multifunctional exosome with dual homeostasis disruption augments cGAS-STING-mediated tumor immunotherapy by boosting ferroptosis. Nano Lett 24(45):14263\u201314272. https:\/\/doi.org\/10.1021\/acs.nanolett.4c03862","journal-title":"Nano Lett"},{"issue":"1","key":"747_CR101","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12943-022-01536-6","volume":"21","author":"SY Wu","year":"2022","unstructured":"Wu SY, Xu Y, Chen L, Fan L, Ma XY, Zhao S, Song XQ, Hu X, Yang WT, Chai WJ, Guo XM, Chen XZ, Xu YH, Zhu XY, Zou JJ, Wang ZH, Jiang YZ, Shao ZM (2022) Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial. Mol Cancer 21(1):84. https:\/\/doi.org\/10.1186\/s12943-022-01536-6","journal-title":"Mol Cancer"},{"issue":"24","key":"747_CR102","doi-asserted-by":"publisher","first-page":"25575","DOI":"10.1021\/acsnano.3c09734","volume":"17","author":"Q Wu","year":"2023","unstructured":"Wu Q, Tan L, Ren X, Fu C, Chen Z, Ren J, Ma T, Meng X (2023) Metal-organic framework-based nano-activators facilitating microwave combined therapy via a divide-and-conquer tactic for triple-negative breast cancer. ACS Nano 17(24):25575\u201325590. https:\/\/doi.org\/10.1021\/acsnano.3c09734","journal-title":"ACS Nano"},{"key":"747_CR103","doi-asserted-by":"publisher","DOI":"10.1002\/anie.202417592","author":"Y Xie","year":"2024","unstructured":"Xie Y, Wang J, Li L, Wang M, Sun J, Chang J, Lin J, Li C (2024) A metal chelation therapy to effectively eliminate breast cancer and intratumor bacteria while suppressing tumor metastasis by copper depletion and zinc ions surge. Angew Chem Int Ed Engl. https:\/\/doi.org\/10.1002\/anie.202417592","journal-title":"Angew Chem Int Ed Engl"},{"key":"747_CR104","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202305526","author":"G Xing","year":"2023","unstructured":"Xing G, Yu X, Zhang Y, Sheng S, Jin L, Zhu D, Mei L, Dong X, Lv F (2023) Macrophages-based biohybrid microrobots for breast cancer photothermal immunotherapy by inducing pyroptosis. Small. https:\/\/doi.org\/10.1002\/smll.202305526","journal-title":"Small"},{"key":"747_CR105","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2025.1550089","volume":"13","author":"Y Xu","year":"2025","unstructured":"Xu Y, Reheman A, Feng W (2025) Recent research progress on metal ions and metal-based nanomaterials in tumor therapy. Front Bioeng Biotechnol 13:1550089. https:\/\/doi.org\/10.3389\/fbioe.2025.1550089","journal-title":"Front Bioeng Biotechnol"},{"issue":"4","key":"747_CR106","doi-asserted-by":"publisher","first-page":"348","DOI":"10.3760\/cma.j.cn112152-20210811-00606","volume":"45","author":"YQ Yang","year":"2023","unstructured":"Yang YQ, Sun CX, Huang X, Li W, Yin YM (2023a) Treatment of palbociclib in hormone receptor positive breast cancer: a real-world study and efficacy prediction model. Zhonghua Zhong Liu Za Zhi 45(4):348\u2013357. https:\/\/doi.org\/10.3760\/cma.j.cn112152-20210811-00606","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"issue":"1","key":"747_CR107","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cmet.2022.09.021","volume":"35","author":"F Yang","year":"2023","unstructured":"Yang F, Xiao Y, Ding J-H, Jin X, Ma D, Li D-Q, Shi J-X, Huang W, Wang Y-P, Jiang Y-Z, Shao Z-M (2023b) Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab 35(1):84-100.e108. https:\/\/doi.org\/10.1016\/j.cmet.2022.09.021","journal-title":"Cell Metab"},{"issue":"1","key":"747_CR108","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.cmet.2022.09.021","volume":"35","author":"F Yang","year":"2023","unstructured":"Yang F, Xiao Y, Ding JH, Jin X, Ma D, Li DQ, Shi JX, Huang W, Wang YP, Jiang YZ, Shao ZM (2023c) Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. Cell Metab 35(1):84-100 e108. https:\/\/doi.org\/10.1016\/j.cmet.2022.09.021","journal-title":"Cell Metab"},{"key":"747_CR109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1466180","volume":"15","author":"H Yang","year":"2024","unstructured":"Yang H, Li G, Zhang J, Zhao J, Zhao Y, Wu Y, Sun Z, Song S, Zou Y, Zou Z, Han X, Deng B, Wang L, Rao H, Xu G, Wang S, Guo S, Ding H, Shi Y, Chen J (2024) A novel hollow iron nanoparticle system loading PEG-Fe(3)O(4) with C5a receptor antagonist for breast cancer treatment. Front Immunol 15:1466180. https:\/\/doi.org\/10.3389\/fimmu.2024.1466180","journal-title":"Front Immunol"},{"key":"747_CR110","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.bioactmat.2024.10.021","volume":"44","author":"T Yang","year":"2025","unstructured":"Yang T, Dai L, Liu J, Lu Y, Pan M, Pan L, Ye L, Yuan L, Li X, Bei Z, Qian Z (2025a) Metal-phenolic-network-coated gold nanoclusters for enhanced photothermal\/chemodynamic\/immunogenic cancer therapy. Bioact Mater 44:447\u2013460. https:\/\/doi.org\/10.1016\/j.bioactmat.2024.10.021","journal-title":"Bioact Mater"},{"issue":"1","key":"747_CR111","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02443-2","volume":"24","author":"C Yang","year":"2025","unstructured":"Yang C, Li S, Wang L (2025b) Engineered iron oxide nanoplatforms: reprogramming immunosuppressive niches for precision cancer theranostics. Mol Cancer 24(1):225. https:\/\/doi.org\/10.1186\/s12943-025-02443-2","journal-title":"Mol Cancer"},{"key":"747_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2019.119309","volume":"217","author":"W Yu","year":"2019","unstructured":"Yu W, He X, Yang Z, Yang X, Xiao W, Liu R, Xie R, Qin L, Gao H (2019) Sequentially responsive biomimetic nanoparticles with optimal size in combination with checkpoint blockade for cascade synergetic treatment of breast cancer and lung metastasis. Biomaterials 217:119309. https:\/\/doi.org\/10.1016\/j.biomaterials.2019.119309","journal-title":"Biomaterials"},{"key":"747_CR113","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1016\/j.jconrel.2024.06.059","volume":"372","author":"H Zafar","year":"2024","unstructured":"Zafar H, Zhang J, Raza F, Pan X, Hu Z, Feng H, Shen Q (2024) Biomimetic gold nanocages incorporating copper-human serum albumin for tumor immunotherapy via cuproptosis-lactate regulation. J Control Release 372:446\u2013466. https:\/\/doi.org\/10.1016\/j.jconrel.2024.06.059","journal-title":"J Control Release"},{"issue":"4","key":"747_CR114","doi-asserted-by":"publisher","first-page":"875","DOI":"10.18388\/abp.2020_6722","volume":"70","author":"X Zhang","year":"2023","unstructured":"Zhang X, Zhang Q (2023) A novel ferroptosis-related gene signature associated with cuproptosis for predicting overall survival in breast cancer patients. Acta Biochim Pol 70(4):875\u2013884. https:\/\/doi.org\/10.18388\/abp.2020_6722","journal-title":"Acta Biochim Pol"},{"issue":"41","key":"747_CR115","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202206915","volume":"34","author":"L Zhang","year":"2022","unstructured":"Zhang L, Zhao J, Hu X, Wang C, Jia Y, Zhu C, Xie S, Lee J, Li F, Ling D (2022) A peritumorally injected immunomodulating adjuvant elicits robust and safe metalloimmunotherapy against solid tumors. Adv Mater 34(41):e2206915. https:\/\/doi.org\/10.1002\/adma.202206915","journal-title":"Adv Mater"},{"key":"747_CR116","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.2147\/IJN.S418100","volume":"18","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Han X, Wang K, Liu D, Ding X, Hu Z, Wang J (2023) Co-delivery nanomicelles for potentiating TNBC immunotherapy by synergetically reshaping CAFs-mediated tumor stroma and reprogramming immunosuppressive microenvironment. Int J Nanomedicine 18:4329\u20134346. https:\/\/doi.org\/10.2147\/IJN.S418100","journal-title":"Int J Nanomedicine"},{"key":"747_CR117","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202402349","author":"W Zhang","year":"2024","unstructured":"Zhang W, Ran Y, Yang M, Hu Y, Wang Z, Cao Y, Ran H (2024a) An oxidative stress nano-amplifier for improved tumor elimination and combined immunotherapy. Adv Healthc Mater. https:\/\/doi.org\/10.1002\/adhm.202402349","journal-title":"Adv Healthc Mater"},{"key":"747_CR118","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2024.122695","volume":"311","author":"P Zhang","year":"2024","unstructured":"Zhang P, Zhong D, Yu Y, Wang L, Li Y, Liang Y, Shi Y, Duan M, Li B, Niu H, Xu Y (2024b) Integration of STING activation and COX-2 inhibition via steric-hindrance effect tuned nanoreactors for cancer chemoimmunotherapy. Biomaterials 311:122695. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122695","journal-title":"Biomaterials"},{"issue":"17","key":"747_CR119","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202100616","volume":"33","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Gong Z, Li Z, Wang J, Zhang J, Zhao Z, Zhang P, Zheng S, Miron RJ, Yuan Q, Zhang Y (2021) Target reprogramming lysosomes of CD8+ T cells by a mineralized metal-organic framework for cancer immunotherapy. Adv Mater 33(17):e2100616. https:\/\/doi.org\/10.1002\/adma.202100616","journal-title":"Adv Mater"},{"key":"747_CR120","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2022.121988","volume":"293","author":"Y Zheng","year":"2023","unstructured":"Zheng Y, Chen J, Song XR, Chang MQ, Feng W, Huang H, Jia CX, Ding L, Chen Y, Wu R (2023) Manganese-enriched photonic\/catalytic nanomedicine augments synergistic anti-TNBC photothermal\/nanocatalytic\/immuno-therapy via activating cGAS-STING pathway. Biomaterials 293:121988. https:\/\/doi.org\/10.1016\/j.biomaterials.2022.121988","journal-title":"Biomaterials"},{"key":"747_CR121","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinorgbio.2024.112695","author":"Y-S Zhi","year":"2024","unstructured":"Zhi Y-S, Chen T, Liang B-F, Jiang S, Yao D-H, He Z-D, Li C-Y, He L, Pan Z-Y (2024) Endoplasmic reticulum-targeted iridium(III) photosensitizer induces pyroptosis for augmented tumor immunotherapy. J Inorg Biochem. https:\/\/doi.org\/10.1016\/j.jinorgbio.2024.112695","journal-title":"J Inorg Biochem"},{"issue":"11","key":"747_CR122","doi-asserted-by":"publisher","first-page":"5083","DOI":"10.1021\/acs.nanolett.3c01008","volume":"23","author":"H Zhong","year":"2023","unstructured":"Zhong H, Chen G, Li T, Huang J, Lin M, Li B, Xiao Z, Shuai X (2023) Nanodrug augmenting antitumor immunity for enhanced TNBC therapy via pyroptosis and cGAS-STING activation. Nano Lett 23(11):5083\u20135091. https:\/\/doi.org\/10.1021\/acs.nanolett.3c01008","journal-title":"Nano Lett"},{"key":"747_CR123","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.actbio.2022.01.019","volume":"141","author":"C Zhu","year":"2022","unstructured":"Zhu C, Ma Q, Gong L, Di S, Gong J, Wang Y, Xiao S, Zhang L, Zhang Q, Fu JJ, Lu D, Lin Z (2022) Manganese-based multifunctional nanoplatform for dual-modal imaging and synergistic therapy of breast cancer. Acta Biomater 141:429\u2013439. https:\/\/doi.org\/10.1016\/j.actbio.2022.01.019","journal-title":"Acta Biomater"},{"issue":"1","key":"747_CR124","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-025-03669-4","volume":"23","author":"S Zhu","year":"2025","unstructured":"Zhu S, Xu W, Li H, Sun Z, Zhu Y, Liu W, Chu H (2025) Metal-organic frameworks activate the cGAS-STING pathway for cancer immunotherapy. J Nanobiotechnology 23(1):578. https:\/\/doi.org\/10.1186\/s12951-025-03669-4","journal-title":"J Nanobiotechnology"},{"issue":"3","key":"747_CR125","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1166\/jbn.2019.2697","volume":"15","author":"Y Zhuo","year":"2019","unstructured":"Zhuo Y, Chen F, Kong L, Li T, Lu L, Yang J, Yu T, Shi X, Li K (2019) Magnetic resonance imaging of the human ferritin heavy chain reporter gene carried by dendrimer-entrapped gold nanoparticles. J Biomed Nanotechnol 15(3):518\u2013530. https:\/\/doi.org\/10.1166\/jbn.2019.2697","journal-title":"J Biomed Nanotechnol"}],"container-title":["BioMetals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10534-025-00747-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10534-025-00747-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10534-025-00747-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T09:09:47Z","timestamp":1765184987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10534-025-00747-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,9]]},"references-count":125,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["747"],"URL":"https:\/\/doi.org\/10.1007\/s10534-025-00747-w","relation":{},"ISSN":["0966-0844","1572-8773"],"issn-type":[{"value":"0966-0844","type":"print"},{"value":"1572-8773","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,9]]},"assertion":[{"value":"8 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"No applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors have read and approved the content and agree to publish.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}